Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest Vanda Pharmaceuticals Inc. Stories

2012-07-05 14:22:05

WASHINGTON, July 5, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that Robert Repella, Vanda's Chief Commercial Officer, will deliver a corporate presentation at the JMP Healthcare Conference in New York City on Friday, July 13, 2012 at 1:00 p.m. Eastern Time. Mr. Repella's presentation at the JMP Healthcare...

2012-06-18 02:26:38

WASHINGTON, June 18, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), announced today that Michael Cola has joined Vanda's Board of Directors. Mr. Cola will also serve as a member of the Audit Committee of the Board replacing Howard Pien, who will continue to serve as the Chairman of the Board and as a member of each of the Compensation Committee and the Nominating/Corporate Governance Committee of the Board. In connection with Mr. Cola's election, the Board has increased the...

2012-06-11 02:25:13

BOSTON, June 11, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, announced today that data presented at SLEEP, the 26th annual meeting of the Associated Professional Sleep Societies (APSS), show that seventy percent (70%) of totally blind people with sleep complaints suffer from Non-24-Hour Disorder (Non-24). Non-24 is a circadian...

2012-06-04 02:25:22

WASHINGTON, June 4, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that the Company will present five posters during the scientific session at SLEEP 2012 on Monday, June 11. The data presented on the posters are from Vanda's ongoing Phase III program for tasimelteon, a circadian regulator being evaluated to...

2012-05-31 14:23:28

WASHINGTON, May 31, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will hold its 2012 Annual Meeting of Stockholders on Thursday, June 14, 2012, in Washington, D.C. The record date for the Annual Meeting is April 20, 2012. Only stockholders of record as of the close of business on April...

2012-05-29 14:21:15

WASHINGTON, May 29, 2012 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that Mihael H. Polymeropoulos, M.D., Vanda's President and CEO, will deliver a corporate presentation at the Jefferies Global Healthcare Conference in New York City on Monday, June 4, 2012 at 12:30 p.m. Eastern Time. Dr....

2012-05-22 14:21:07

WASHINGTON, May 22, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, announced today that the Company presented two posters at the Society for Research on Biological Rhythms (SRBR) annual meeting in Destin, Florida. The first poster entitled Pleiomorphic Expression of Non-24-Hour Disorder in the Totally Blind, provides insight into the challenges faced...

2012-05-08 02:27:38

WASHINGTON, May 8, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the first quarter ended March 31, 2012. Key Highlights: The tasimelteon Non-24-Hour Disorder (Non-24) program continues to advance towards the goal of a projected mid-2013 New Drug Application (NDA) filing...

2012-02-23 18:00:00

ROCKVILLE, Md., Feb. 23, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will participate in three upcoming investor conferences. On Tuesday, February 28, 2012, Mihael Polymeropoulos, M.D., Vanda's President and CEO, will participate in a Neurology-focused discussion at RBC Capital Markets' Global...

2012-02-14 06:00:00

ROCKVILLE, Md., Feb. 14, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the fourth quarter and twelve months ended December 31, 2011. Key Highlights: Initial clinical data in the RESET study revealed potential of tasimelteon to reset the body clock in Non-24-Hour...